Generate Biomedicines (NASDAQ:GENB) Trading Up 7.9% – Here’s Why

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price was up 7.9% on Monday . The stock traded as high as $16.15 and last traded at $15.6410. 225,803 shares changed hands during trading, a decline of 63% from the average session volume of 616,535 shares. The stock had previously closed at $14.49.

Analyst Ratings Changes

Several brokerages recently commented on GENB. Cantor Fitzgerald assumed coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating for the company. Morgan Stanley lifted their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Piper Sandler initiated coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 target price on the stock. HC Wainwright raised their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Zacks Research raised Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Stock Up 9.3%

The stock has a 50-day moving average of $13.38.

Generate Biomedicines (NASDAQ:GENB) last announced its earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.